Although ECL2 is an effective self‐modulator on GPR21/52 activity, it has been shown that therapeutic modulation via the remote allosteric site is still a feasible approach in treating Huntington's disease and psychiatric disorders.43, 44. This evidence concerns the gene GPR21 and juvenile Huntington disease.